Boncompain C, Orive M, Nipoti J, Reynoso MB, Llahyah Y, Fernández BRA

Language: Spanish
References: 13
Page: 93-97
PDF size: 245.78 Kb.

ABSTRACT

Introduction: Systemic sclerosis (SS), a term that is currently preferred to refer to Systemic Scleroderma, is a disease of genetic etiology, which is characterized by the thickening and adhesion of teguments to deepest planes, hindering their folding. At the beginning of the disease these signs could be subtle. In the systemic form internal organs also suffers those changes. Methodology: To know what happens with this pathology in our environment we carried out a descriptive, retrospective and observational study whose source of information were the clinical histories of the patients who are in control and treatment by the Department of Collagenopathies, belonging to the Dermatology Service of the Hospital Provincial del Centenario. Patients of both sexes were included, from 10 years of age and without age limit. The data were collected from January 2014 to March 2016, and analyzed with EPI INFO 7.0 software (Centers for Disease Control and Prevention 1600 Clifton Rd. Atlanta, GA 30333, USA). Results: The average age of the beginning of the SS is 42.5 years, with female predominance. The Raynaud phenomenon was observed in 81% patients and the sclerodactyly in 96% of them. More frequent comorbidity associations were Sjogren, hypothyroidism and vitiligo. Pulmonary and digestive affectations were observed in a 37% and 63% of patients, respectively. Conclusion: This work allowed us to observe the more frequently comorbid associations presents in our patients and correlated with other results reported in the literature, being the most frequent the Sjogren Syndrome, hypothyroidism and vitiligo. Pulmonary affectation was similar to other reported cases and the digestive slightly lower. We could not observe in this study neither cardiac nor renal disease. The sclerodactyly and Raynaud phenomenon were observed in most patients and the most used drug to treat the last one was retard nifedipine. The importance of performing an early and correct diagnosis to improve the quality of life of patients with systemic scleroderma is highlighted

REFERENCES

1. Consenso sobre esclerodermia. Sociedad Argentina de Dermatología. Actualización 2015. Dra. Mercedes Lidia Hassan. Capítulo Capilaroscopia, Terapéutica Fernández Bussy R.A.

2. Chen K, See A, Shumack S. Epidemiology and pathogenesis of scleroderma. Australas J Dermatol. 2003; 44 (1): 1-7.

3. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009; 360 (19): 1989-2003.

4. Katz SI, Gilchrest BA. Fitzpatrick. Dermatología en Medicina General. 7ª ed. Editorial Médica Panamericana; Buenos Aires; 2009; 543-546 y 1553-1562.

5. Nudenberg B, Hassan. Consenso sobre esclerodermia. Sociedad Argentina de Dermatología, 2006.

6. Diagnóstico, Tratamiento y Pronóstico de la Esclerosis Sistémica. México: Secretaría de Salud, 2010.

7. Silvariño R, Rebella M, Cairoli E. Manifestaciones clínicas en pacientes con esclerosis sistémica. Rev Méd Urug. 2009; 25 (2): 84-91.

8. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al. 2013 Classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013; 72 (11): 1747-1755.

9. Jacobsen S, Halberg P, Ullman S, Van Venrooij WJ, Høier-Madsen M, Wiik A, Petersen J. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic scleroderma. Br J Rheumatol. 1998; 37 (1): 39-45.

10. Badea I, Taylor A, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford). 2009; 48 (3): 213-221.

11. Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the Scleroderma Trials and Research group (EULAR). Ann Rheum Dis. 2009; 68 (6): 856-862.

12. Succaria F, Kurban M, Kibbi AG, Abbas O. Clinicopathological study of 81 cases of localized and systemic scleroderma. J Eur Acad Dermatol Venereol. 2012; 27 (2): e191-e196.

13. Vera LO. Esclerosis sistémica. Med Int Mex. 2006; 22 (3): 231-245.